传奇生物

最新新闻

• 评级变动
  J.P. Morgan Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $41.42
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $58
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $59
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  UBS Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $49
  \u5e02\u573a\u8d44\u8baf · 2026/6/5
• 评级变动
  Oppenheimer Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $63
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Cuts Target Price to $24
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)
  TipRanks · 2026/8/12
• 评级变动
  Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $64
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $74
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)
  TipRanks · 2026/8/12
• H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $48
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $40.5
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  UBS Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $28
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $80
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  UBS Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $49
  \u5e02\u573a\u8d44\u8baf · 2026/6/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。